pexelizumab

DRUG2 trials

Sponsors

Alexion Pharmaceuticals, Inc., Procter and Gamble

Conditions

Acute Myocardial InfarctionCardio-pulmonary BypassCoronary Artery Bypass Graft

Phase 3

Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass

CompletedNCT00048308

Alexion Pharmaceuticals, Inc.Cardio-pulmonary Bypass, Coronary Artery Bypass Graft

Start: 2002-01-31Target: 3000Updated: 2017-02-23

Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)

CompletedNCT00091637

Procter and GambleAcute Myocardial Infarction

Start: 2004-04-30End: 2007-05-31Updated: 2023-11-18

Related Papers

Stroke after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: timing, characteristics, and clinical outcomes.

2013-04-0241 citations

Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial.

2011-02-0822 citations

Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

2010-01-1948 citations

Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.

2010-01-1236 citations

Baseline Q-wave surpasses time from symptom onset as a prognostic marker in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.

2009-04-0152 citations

Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial.

2007-01-01286 citations